For research use only. This reference describes TB-500 strictly as a chemical compound used in cell-based and animal-model research. Research-grade TB-500 is sold for in-vitro laboratory work; nothing here is intended for human or animal consumption, and we make no health, performance, or therapeutic claims of any kind. For full context, see our research-use disclaimer.
TB-500 is a synthetic N-acetylated heptapeptide. Its sequence is Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), corresponding to residues 17-23 of the parent protein thymosin β4. It carries the actin-binding stretch of the parent and shows up across the in-vitro literature as a discrete reagent — narrower in biological scope than the full 43-residue protein, easier to handle, and chemically well-characterized. What follows covers the primary chemistry, the relationship to thymosin β4, the actin-sequestering mechanism, why the N-terminal acetylation is there, the in-vitro endpoints most commonly reported, the in-vitro metabolism profile, and the current regulatory framing.
Sequence and chemistry: an N-acetylated heptapeptide
TB-500 is documented in encyclopedic references as a synthetic peptide with the sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln. Its molecular weight is approximately 860 Da. The seven residues correspond exactly to positions 17 through 23 of the human thymosin β4 sequence, with the N-terminal leucine carrying an acetyl cap on the alpha-amino nitrogen.
The synthesis route is standard solid-phase peptide chemistry. The characterization paper by Sosne and colleagues describes Fmoc chemistry on Wang resin, followed by N-terminal acetylation with acetic anhydride and HPLC purification. Mass spectrometry confirms the expected molecular ion. Circular-dichroism spectra show a largely random-coil conformation in aqueous buffer with modest helical character induced by trifluoroethanol — a profile consistent with the disordered character of the parent thymosin β4 protein, which is itself an intrinsically disordered protein in physiological conditions.
For the in-vitro researcher, the practical implication of the disordered conformation is that the binding-relevant geometry is induced on engagement with the target rather than pre-organized in solution. The peptide does not have a stable solution structure to interrogate; what matters is the bound conformation against G-actin.
Relationship to the parent protein thymosin β4
Thymosin β4 is a 43-amino-acid protein abundant in the cytosol of many cell types. As the encyclopedia entry summarizes, the protein binds globular (G) actin monomers in a 1:1 complex. It does not bind filamentous (F) actin. The 17-23 stretch — the same sequence that becomes TB-500 when synthesized as a discrete peptide — is the activity-essential portion of the parent for that binding interaction.
The choice between the full parent protein and the synthetic heptapeptide is a practical one. The parent is a 43-residue protein with the chromatography and stability behaviour you would expect from any disordered cytosolic protein; the heptapeptide is much smaller, simpler to characterize, and easier to source as a chemically pure reagent. The trade-off is biological scope: the parent carries the rest of the sequence flanking 17-23, and that flanking material may contribute to non-actin activities the heptapeptide misses.
Researchers comparing the two should report which one was used and at what concentration. Direct equivalence between TB-500 and full-length thymosin β4 has not been established for every endpoint reported in the literature.
The actin-sequestration mechanism
The foundational biochemistry is straightforward. Thymosin β4 — and the LKKTET stretch within it — binds G-actin in a 1:1 complex, holding the actin monomer in a state that blocks polymerization into filaments. The result, in cells and in cell-free assays, is depletion of the polymerization-competent actin pool. Cells with more thymosin β4 (or more synthetic LKKTETQ) have less polymerization-competent G-actin available; the dynamic equilibrium between G-actin and F-actin tilts toward the monomer.
The study by Philp and colleagues localizes the actin-binding activity to the LKKTET segment specifically. Synthetic peptides corresponding to that minimum motif retain the parent protein's actin-sequestering activity and produce measurable effects on endothelial cell migration and tube formation in cell-culture assays. The seventh residue (Gln23) extends the segment to the LKKTETQ form used in TB-500, but the minimum binding motif is the six-residue LKKTET.
For the in-vitro researcher, this means the relevant readouts are the polymerization-dependent ones: scratch-wound migration where leading-edge actin assembly limits the rate of closure, Matrigel tube formation where endothelial-cell shape changes depend on actin reorganization, and any assay that responds to changes in the G-actin / F-actin ratio. Endpoints that don't depend on the actin cytoskeleton are unlikely to register a TB-500-induced signal.
Why N-terminal acetylation: stability rationale
The N-terminal acetyl group on TB-500 is not decorative. It serves a specific biochemical purpose: aminopeptidases otherwise cleave the leucine off the N-terminus of the unmodified heptapeptide, producing the truncated and functionally weaker LKKTETQ-minus-Leu fragment. Acetylation caps the alpha-amino nitrogen of leucine and shuts off that cleavage path. The peptide persists substantially longer in serum and in cell-culture media as a result.
The characterization paper reports stability data on both forms in serum incubation. The acetylated form retains its actin-binding mode — the modification is stability-only, not activity-altering. This separation is exactly what the medicinal-chemistry literature looks for: a stability cap that does not interfere with the binding-relevant residues.
For experimental design, the practical consequence is that timecourses run with TB-500 can extend over hours or days without concentration falling off as quickly as it would for the unmodified heptapeptide. Re-spiking the medium during long incubations is generally unnecessary at typical assay concentrations.
In-vitro endpoints reported across the literature
The published in-vitro work on TB-500 clusters around endpoints that are sensitive to actin-cytoskeleton dynamics. Three classes of assay appear most often.
The first is scratch-wound migration. Cultured dermal fibroblasts or human umbilical vein endothelial cells (HUVECs) are scratched mechanically, and the rate of monolayer closure is measured over 12-48 hours. TB-500 in the medium accelerates closure relative to vehicle controls in both fibroblast and endothelial preparations. The analytical-chemistry paper by Liu and colleagues reports scratch-wound assays with both the parent peptide and its in-vitro metabolites.
The second is Matrigel tube formation. HUVECs plated on Matrigel reorganize within hours into tube-like networks that approximate vascular morphology. TB-500 increases the number and length of tubes formed compared with vehicle controls. The Philp study reports tube-formation data alongside the actin-binding mechanism, anchoring the cell-level observation in the molecular biochemistry.
The third class is mast-cell exocytosis. The paper by Cassimeris and colleagues shows that thymosin β4 and 17-23-class peptides both trigger exocytosis of granular contents from cultured rat mast cells in a concentration- and time-responsive manner. This is a non-actin secondary activity localized to the same stretch — the same molecular fragment researchers commonly study for actin-sequestration shows additional cell-biological activity in mast-cell preparations.
Across all three endpoints, the readouts are receptor- and process-specific; pairing the actin-related assays with the mast-cell assay in a single study captures more of the molecule's in-vitro activity profile than either alone.
In-vitro metabolism and secondary activity
Liver-microsome incubation studies provide the metabolism profile. The Liu paper incubated TB-500 with rat and human liver microsomes and identified the major in-vitro metabolites by UHPLC-Q-Exactive orbitrap MS/MS. The dominant transformation is N-deacetylation, producing the unmodified LKKTETQ heptapeptide. Shorter peptide fragments — products of progressive aminopeptidase digestion — appear at lower concentrations.
The same paper screened the metabolites for in-vitro wound-healing activity. The deacetylated LKKTETQ retained migration-promoting activity in scratch-wound assays in cultured fibroblasts. The shorter fragments did not. The activity-relevant length is therefore the full seven residues; the acetyl group affects stability but not direct activity.
The mast-cell exocytosis activity reported by the Cassimeris paper rounds out the secondary-activity picture. The same 17-23 stretch that binds G-actin also triggers exocytosis in cultured mast cells; whether the two activities share a downstream mechanism is an open question in the literature.
Regulatory framing
TB-500 has no FDA approval for human therapeutic use. The compound is appearing on the July 23-24, 2026 PCAC agenda for potential addition to the section 503A Bulks List — a question about pharmacy compounding eligibility, not about research-grade chemical supply. The two regulatory tracks are distinct and the outcome of one does not directly determine the other.
Optides supplies TB-500 as a research-grade reagent for in-vitro laboratory work only. The chemistry is identical to what the published literature characterizes; the regulatory framework, intended use, and quality-control posture differ from any pharmacy-compounded preparation. For broader context on how this is structured, see our retatrutide structural piece for a peptide-chemistry sister article and the research-use legal landscape article for the surrounding framework.
Frequently Asked Questions
What is TB-500 and how is it different from thymosin β4?
TB-500 is a synthetic N-acetylated heptapeptide with the sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), corresponding to residues 17-23 of the 43-residue parent protein thymosin β4. It carries the actin-binding stretch of the parent protein but not the rest of the sequence. Researchers use the heptapeptide as a discrete reagent in in-vitro work where the full parent protein would be unwieldy.
Why is TB-500 N-acetylated?
The N-terminal acetylation slows degradation of the peptide by aminopeptidases that would otherwise cleave the leucine off the N-terminus. The acetyl group caps the alpha-amino nitrogen, extending the peptide's stability in serum and cell-culture media without altering its actin-binding mode. Stability studies show the acetylated form persists substantially longer than the unmodified heptapeptide.
What does "actin sequestration" actually mean for the in-vitro researcher?
Thymosin β4 binds globular (G) actin monomers in a 1:1 complex; it does not bind filamentous (F) actin. Holding actin in the monomeric pool blocks polymerization into filaments. The LKKTET stretch is the minimum motif required for this binding. In cell-culture assays, this translates to measurable effects on cell migration and on the polymerization-dependent endpoints (tube formation, wound-edge closure) that depend on actin-cytoskeleton turnover.
Is TB-500 approved for human use?
No. TB-500 has no FDA approval for human therapeutic use. It is appearing on the July 2026 PCAC agenda for potential inclusion on the section 503A Bulks List — a separate question from research-grade chemical supply. Optides supplies TB-500 as a research-grade reagent for in-vitro laboratory work only; research-grade material is not for human or animal consumption.
What in-vitro endpoints are most commonly reported with TB-500?
Cell-culture endpoints reported across the published literature include scratch-wound migration assays (typically in dermal fibroblasts or HUVECs), Matrigel tube-formation assays in endothelial cells, and mast-cell exocytosis. Liver-microsome incubation studies identify the major in-vitro metabolites — primarily the deacetylated form and shorter peptide fragments. The deacetylated form retains migration-promoting activity in scratch-wound assays; shorter fragments do not.
Conclusion
TB-500 is a structurally well-defined synthetic peptide: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, corresponding to the 17-23 stretch of thymosin β4, with an acetyl cap on the N-terminal leucine that extends serum stability without altering activity. The mechanism — 1:1 G-actin binding, F-actin avoidance — anchors the in-vitro endpoints reported across the literature: scratch-wound migration, Matrigel tube formation, and a non-actin secondary activity in mast-cell exocytosis. Liver-microsome metabolism produces a deacetylated form that retains activity and shorter fragments that don't. The compound has no FDA approval and is appearing on the July 2026 PCAC agenda for separate consideration; research-grade material remains a distinct supply category. For research use only.
For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.
Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.